期刊文献+

基于cell-SELEX技术筛选高转移胃癌细胞系HGC-27核酸适配体

Cell-SELEX-based selection of aptamers for targeting high metastatic gastric canceetastatic gastric cancer cells (HGC-27)
下载PDF
导出
摘要 目的筛选针对高转移胃癌细胞(HGC-27)的核酸适配体。方法以HGC-27为靶细胞,以AGS为反筛细胞,利用Cell-SELEX技术逐轮次筛选,从文库中挑选能与HGC-27结合的核酸适配体LW-25。用流式细胞术检测核酸适配体测富集程度,核酸适配体与HGC-27的亲和力及特异性。结果流式细胞仪显示随着筛选轮数的增加,次级文库与靶细胞结合的荧光强度增强。从次级文库中成功挑选出一条能与HGC-27结合的核酸适配体LW-25。并且LW-25能特异性识别HGC-27。胰蛋白酶处理HGC-27后,LW-25与HGC-27的结合能力较处理前明显下降。结论核酸适配体LW-25能特异性识别HGC-27,是潜在具有诊断胃癌转移的分子探针。 Objective To screen aptamers binding highly metastatic gastric cancer cells(HGC-27). Methods HGC-27 cells were selected as targeted cells and AGS cells were selected as negative cells.A DNA aptamer named LW-25 was successfully selected against HGC-27 cells by using the cell-based systematic evolution of ligands by exponential enrichment (SELEX) method.Flow cytometry was used to monitor the enrichment of the selected DNA pool,and to evaluate the selectivity and the binding affinities of LW-25. Results The subpools binding against HGC-27 cells increased along with selection rounds.We successfully selected a aptamer named LW-25 which could specifically bind against HGC-27 cells.Furthermore,trypsin treatment greatly reduced the binding of LW-25 to HGC-27 cells. Conclusion These studies demonstrated that this HGC-27 specific aptamer LW-25 may be a potential molecular probe to recognize metastatic gastric cancer cells.
作者 刘涛 王进军 方晓娜 何磊 杨伟丽 罗昭锋 王亚雷 Liu Tao;Wang Jinjun;Fang Xiaona(Division of Gastroenterology,The First Affiliated Hospital of Anhui Medical University,Hefei230022;School of Life Sciences,University of Science and Technology of China,Hefei230027)
出处 《安徽医科大学学报》 CAS 北大核心 2019年第6期933-937,共5页 Acta Universitatis Medicinalis Anhui
基金 安徽省公益性技术应用研究联动计划项目(编号:15011d04043)
关键词 核酸适配体 胃癌 转移 aptamer gastric cancer metastasis
  • 相关文献

参考文献1

二级参考文献23

  • 1Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61: 69-90.
  • 2Bruix J and Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011, 53: 1020-1022.
  • 3Schwartz M, Roayaie S and Konstadoulakis M. Strategies for the manage- ment ofhepatoeellular carcinoma. Nat Clin Pmct Onco12007, 4:424- 432.
  • 4Tuerk C and Gold L. Systematic evolution of ligands by exponential enrich- ment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990, 249:505- 510.
  • 5Wu X, Ding BY, Gao J, Wang HY, Fan W, Wang X and Zhang W, et al. Second-generation aptamer-conjugated PSMA-targeted defNery system for prostate cancer therapy. Int J Nanomedicine 2011, 6:1747-1756.
  • 6Zhang K, Sefah K, Tang L, Zhao Z, Zhu G, Ye M and Sun W, et al. A novel aptamer developed for breast cancer cell internalization. ChemMedChem 2012.7: 79-84.
  • 7Ng EWM, Shima DT, Calias P, Cunningham ET, Guyer DR and Adamis AP. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006, 5:123-132.
  • 8Fang XH and Tan WH. Aptamers generated from cell-SELEX for molecular medicine: a chemical biology approach. Acc Chem Res 2010, 43: 48-57.
  • 9Shangguan D, Li Y, Tang ZW, Cao ZHC, Chen HW, Mallikamtchy P and Sefah K, et al. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Natl Acad Sci USA 2006, 103: 11838-11843.
  • 10Shangguan D, Meng L, Cao ZC, Xiao Z, Fang X, Li Y and Cardona D, et al. Identification of liver cancer-specific aptamers using whole live cells. Anal Chem 2008, 80:721-728.

共引文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部